A Randomized Study of mTOR Inhibition by RAD001 (Everolimus) in Invasive Breast Cancer Patients After Pre-operative Use of Anthracycline and/or Taxane-based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 23 May 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 20 Mar 2010 New trial record